Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

4.12

Mkt cap

48M

Volume

1.1M

High

4.28

P/E Ratio

-1.90

52-wk high

7.33

Low

3.60

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has regained compliance with Nasdaq's minimum market value of listed securities requirement, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from

January 21, 2025 | 1:15 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has appointed Michael Taylor to its Board of Directors and Anita Nunes as a Board Observer. Nunes will also be appointed Director of HOPE Therapeutics, Inc., a subsidiary of NRx.

Portfolio Pulse from

January 15, 2025 | 1:15 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, highlighted a CNN program featuring Dr. David Feifel discussing ketamine. Kadima Neuropsychiatry Institute, founded by Dr. Feifel, is set to become HOPE's flagship clinic upon acquisition closure.

Portfolio Pulse from

January 14, 2025 | 1:15 pm

NRx Pharmaceuticals, Inc. has applied to NASDAQ to uplist from the NASDAQ Capital Market to the NASDAQ Global Market, which could improve shareholder liquidity. The company currently has 15.7 million shares outstanding.

Portfolio Pulse from

January 13, 2025 | 1:15 pm

HOPE Therapeutics and NRx Pharmaceuticals will present a keynote on combined interventional treatment for suicidal depression and PTSD at the Neuroscience Innovation Forum. NRx has filed an NDA for NRX-100, and HOPE plans acquisitions to expand its psychiatry clinics.

Portfolio Pulse from

January 07, 2025 | 1:15 pm

NRXP, PDEX, and PBYI have been identified as top momentum stocks by Zacks Rank #1 (Strong Buy) for January 6, 2024.

Portfolio Pulse from

January 06, 2025 | 4:45 pm

HOPE Therapeutics and NRx Pharmaceuticals have signed a binding term sheet for $27 million in funding. This includes $25 million in Series A Preferred Stock for HOPE Therapeutics, convertible into equity, with a 15% dividend, to support clinic acquisitions and NRx operations.

Portfolio Pulse from

January 06, 2025 | 3:30 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, plans to acquire Dura Medical to establish a network of interventional psychiatry clinics in Florida. This acquisition is expected to boost NRx's revenue and EBITDA.

Portfolio Pulse from

January 06, 2025 | 1:30 pm

Hope Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), plans to acquire Kadima Neuropsychiatry Institute to establish an international network of interventional psychiatry clinics. This acquisition is expected to be immediately accretive to NRx's revenue and EBITDA.

Portfolio Pulse from

January 02, 2025 | 1:30 pm

NRx Pharmaceuticals, Inc. has filed the initial section of a New Drug Application with the FDA for NRX-100, an IV Ketamine treatment for suicidal depression. The company aims to complete the NDA filing by Q1 2025 and will participate in the J.P. Morgan Healthcare Conference in January 2025.

Portfolio Pulse from

December 30, 2024 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.